Trial Profile
A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety an Efficacy of AG-013958 in Subjects With Subfoveal Choroidal Neovascularization Associated With Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 May 2014
Price :
$35
*
At a glance
- Drugs AG 13958 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Pfizer
- 21 May 2014 New trial record